NO-releasing polypeptide nanocomposites reverse cancer multidrug resistance via triple therapies

Yue Ding,Yuxuan Ma,Chang Du,Chenwei Wang,Tingting Chen,Yang Wang,Jin Wang,Yong Yao,Chang-Ming Dong
DOI: https://doi.org/10.1016/j.actbio.2021.01.015
IF: 10.633
2021-03-01
Acta Biomaterialia
Abstract:<p>Multidrug resistance (MDR) induced by the overexpression of P-glycoprotein (P-gp) transporters mainly leads to chemotherapy (CT) failure. Herein, a NIR/pH dual-sensitive charge-reversal polypeptide nanocomposite (PDA-PLC) was developed for co-delivering a nitric oxide (NO) donor and doxorubicin (DOX). Under near-infrared (NIR) irradiation, the released high-concentration of NO gas inhibited the P-gp expression to sensitize the chemotherapeutic medicine DOX and assisted photothermal therapy (PTT) to eradicate cancer cells without skin scarring. Further, the distinctive charge-reversal capacity of PDA-PLC significantly facilitated cellular uptake in the tumor acidic microenvironment (pH 6.8) and enhanced its stability in the physiological environment (pH 7.4). This DOX-loading polypeptide nanocomposite (PDA-PLC/DOX) provides an effective strategy for the PTT-NO-CT triple-combination therapy to overcome MDR.</p>
engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?
This paper aims to solve the problem of multidrug resistance (MDR), especially the chemotherapy failure problem caused by the over - expression of P - glycoprotein (P - gp) transporter. The authors developed a near - infrared (NIR)/pH dual - sensitive charge - reversing polypeptide - based nanocomposite (PDA - PLC) for the co - delivery of nitric oxide (NO) donors and doxorubicin (DOX). Through the triple - combination therapy of photothermal therapy (PTT), NO gas therapy and chemotherapy (CT), this nanocomposite can effectively reverse cancer multidrug resistance and eradicate cancer cells without leaving skin scars. Specifically, the main objectives of this study include: 1. **Overcoming multidrug resistance**: By inhibiting the expression of P - glycoprotein, increasing the intracellular accumulation of chemotherapy drugs, thereby enhancing the chemotherapy effect. 2. **Improving cell uptake**: Utilizing the charge - reversing property of the nanocomposite in the tumor acidic microenvironment to significantly promote cell uptake. 3. **Achieving controlled release**: Triggered by near - infrared light, achieving the precise release of NO gas and chemotherapy drugs, improving the spatiotemporal controllability and minimally invasive nature of the treatment. 4. **Enhancing the treatment effect**: Combining photothermal therapy, NO gas therapy and chemotherapy to achieve a synergistic effect and completely eradicate MCF - 7/ADR tumors. ### Main methods and techniques - **Preparation of nanocomposite**: The PDA - PLC nanocomposite was prepared through polymer self - assembly and surface modification. - **Charge - reversing property**: At physiological pH 7.4, the nanocomposite is negatively charged and stable; at tumor microenvironment pH 6.8, the charge is reversed to positive, promoting cell uptake. - **Photothermal effect**: Under near - infrared light irradiation, PDA - PLC generates heat to achieve photothermal therapy. - **NO gas release**: Near - infrared light triggers the release of NO gas, inhibiting the expression of P - glycoprotein. - **Drug release**: Dual - triggered by near - infrared light and pH change, the release of DOX is achieved, improving drug efficacy. ### Experimental results - **Charge - reversing property**: PDA - PLC rapidly changes from negative to positive at pH 6.8, significantly increasing cell uptake. - **Photothermal effect**: The temperature of PDA - PLC increases significantly under near - infrared light irradiation, having a good photothermal conversion efficiency. - **NO gas release**: Near - infrared light triggers the rapid release of NO gas, effectively inhibiting the expression of P - glycoprotein. - **Drug release**: Dual - triggered by pH and near - infrared light, the release of DOX is achieved, increasing the drug accumulation at the tumor site. - **Cell experiments**: PDA - PLC/DOX shows significant cytotoxicity and P - glycoprotein inhibition effects in MCF - 7/ADR cells. - **Animal experiments**: PDA - PLC/DOX significantly inhibits tumor growth in vivo experiments without obvious side effects. ### Conclusion This study provides an effective strategy. Through the PDA - PLC nanocomposite, the triple - combination therapy of photothermal therapy, NO gas therapy and chemotherapy is achieved, successfully overcoming multidrug resistance and providing new ideas for cancer treatment.